According to the latest market report published by Credence Research, Inc. “Antinuclear Antibody Tests Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025,” the global antinuclear antibody tests market was valued at US$ 649 Mn in 2016, and is expected to reach US$ 1,588.7 Mn by 2025, expanding at a CAGR of 9.8% from 2017 to 2025
Browse the full report Antinuclear Antibody Tests Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 at https://www.credenceresearch.com/report/anti-nuclear-antibody-testing-ana-market
An antinuclear antibody tests (ANA) are used to evaluate quantity and pattern of antibodies in the blood. It is used to evaluate autoimmune disorders that might affect tissues and organ throughout systemic body. It is commonly used to diagnose rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren syndrome, scleroderma and polymyositis. Usually any foreign body such as virus or bacteria if enters the body, would be destroyed by the immune system. In autoimmune disorder, body produces ANA as group of antibodies, as the immune system is not able to differentiate between “self” and “nonself.” It targets the nucleus of the cell and destroys the tissue and the organ. Rising prevalence of autoimmune disorders, advancement in lab automation and use of novel biomarker are the key factors driving the growth of antinuclear antibody tests market
The global antinuclear antibody tests market is segmented by product type into reagent & assays kits, systems and software & services. Reagents and assay kits occupy the largest share of global antinuclear antibody tests market. The global antinuclear antibody tests market is segmented by technique type into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay and multiplex assay. Enzyme-Linked Immunosorbent Assay (ELISA) dominates the global antinuclear antibody tests market. By disease, global antinuclear antibody tests market is segmented into rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma and other diseases. Rheumatoid arthritis currently occupies the largest market share of global antibody tests market due to rising prevalence of rheumatoid arthritis.
As of the current market scenario, North America dominated the global antinuclear antibody tests market followed by the Europe. Factors contributing to the growth of North America market includes increase in prevalence of autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), growing introduction and availability of novel diagnostic tools and supportive reimbursement policies. Asia Pacific is the fastest growing regional market for antinuclear antibody tests.
Market Competition Assessment:
Key players in the global antinuclear antibody test market are Alere, Inc., EUROIMMUN AG, ERBA Diagnostics, Inc., Trinity Biotech plc, Bio-Rad Laboratories, Inc., Immuno Concepts, Thermo Fisher Scientific, Inc., Antibodies, Inc., Inova Diagnostics, Zeus Scientific, Inc. and others.
Key Market Movements:
– Rising awareness about autoimmune disorders and availability of novel diagnostic tools and kits also contribute to the growth of antinuclear antibody tests market
– Prevalence of diagnosed autoimmune conditions is highest in EU-5 with 9%, followed by China and U.S. with 8% and 7% respectively. Autoimmune diseases is one of leading cause of mortality in developed countries. Thus rising prevalence of autoimmune disorder is the pivotal factor driving the growth of antinuclear antibody tests market